Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Genentech, Inc.

F. Hoffmann-la Roche Ag

Jutta Wanner

Johannes Cornelius Hermann

Matthew C Lucas

Andreas Kuglstatter

Francisco Xavier Talamas

Sharada Shenvi Labadie

Shaoqing Chen

Clara Jeou Jen Lin

Fernando Padilla

Xiaohu Zhang

Nidhi Arora

Amy Geraldine Moore

Yansheng Zhai

Eva Papp

Yan Lou

Yimin Qian

Sung-Sau So

Francisco Javier Lopez-Tapia

Kin-Chun Thomas Luk

Timothy D Owens

Roland Joseph Billedeau

Rama K Kondru

Kshitij Chhabilbhai Thakkar

David Mark Rotstein

Chris Richard Melville

Remy Lemoine

Lin Yi

Omar Jose Morales

Wenwei Xie

Lee Edwin Lowrie, Jr

Ann Catherine Petersen

Clara Jeou Lin

Jr Lee Edwin Lowrie

Compounds of the formula I or II: wherein X, m, Ar, Rand Rare as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Imidazopyridazine compounds

The present invention relates to the use of novel thiazolopyrimidine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Thiazolopyrimidine compounds

There are provided compounds of the formula wherein Rand Rare as described herein. The compounds are useful as anticancer agents.

Substituted pyrrolo[1,2-a]pyrazines as tankyrase inhibitors

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R-Rand Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I. 

Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists

Growing community of inventors

Montclair, NJ, United States of America

Jutta Wanner